Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 02:59 am EST
Share
Seegene, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 150,844.1 million compared to KRW 305,309.98 million a year ago. Net loss was KRW 11,069.48 million compared to net income of KRW 92,757.5 million a year ago. Basic loss per share from continuing operations was KRW 217 compared to basic earnings per share from continuing operations of KRW 1,793 a year ago. Basic loss per share was KRW 217 compared to basic earnings per share of KRW 1,793 a year ago.
For the nine months, sales was KRW 730,736.29 million compared to KRW 960,793.72 million a year ago. Net income was KRW 179,552.66 million compared to KRW 372,881.78 million a year ago. Basic earnings per share from continuing operations was KRW 3,523 compared to KRW 7,188 a year ago. Basic earnings per share was KRW 3,523 compared to KRW 7,188 a year ago.
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.
SEEGENE, INC. 
